The lead compound for the RFE and GEN Pharma biotech companies is RFE-007-CAI. This compound is primarily targeted against abnormal vessels that grow under the retina causing severe vision loss through common conditions such as Age Related Macular Degeneration and Diabetic Retinopathy. This molecule may also be an effective treatment for Ocular Toxoplasmosis, a common retinal infection.
RFE-007-CAI has significant advantages over current treatments. It is more stable, reduces the number of necessary injections, and might better preserve the fragile retinal cells affected by these conditions. We anticipate beginning clinical trials on RFE-007-CAI in mid-2010.